Table 2.
Parameters.
| Characteristics | PNET-T | PNET-NT | CTR |
|---|---|---|---|
| SWS in m/s | |||
| mean ± SD | 2.02 ± 0.61 | 1.31 ± 0.18 | 1.26 ± 0.09 |
| (95%-CI) | (1.65–2.39) | (1.20–1.42) | (1.21–1.32) |
| Fluidity expressed as loss angle in rad | |||
| mean ± SD | 1.0 ± 0.17 | 0.78 ± 0.07 | 0.81 ± 0.06 |
| (range) | (0.90–1.10) | (0.74–0.83) | (0.77–0.85) |
| Entity | |||
| Nonfunctional NET | 10/13 (77%) | ||
| Functional NET | 1/13 (8%) * | ||
| Malignant insulinoma | 1/13 (8%) | ||
| NEC | 1/13 (8%) | ||
| Tumor volume in cm3 | |||
| mean ± SD | 55.16 ± 72.05 | ||
| (range) | (0.04–190.53) | ||
| Tumor site (multiple locations possible) | |||
| Head | 5 | ||
| Body | 7 | ||
| Tail | 8 | ||
| Tumor histopathologically proven | 10/13 (77%) | ||
| Grade | |||
| G1 | 1/10 (10%) | ||
| G2 | 8/10 (80%) | ||
| G3 | 1/10 (10%) | ||
| Ki-67 | |||
| mean ± SD | 9 ± 10% | ||
| (range) | 1–30% | ||
| Tumor proven by [68Ga]Ga-DOTATOC PET/CT/PET/MRI |
9/13 (69%) | ||
| SUVmax | |||
| mean ± SD | 45.5 ± 25.6 | ||
| (range) | (13.8–87.9) | ||
| Time between PET/CT/PET/MRI and MRE in months | |||
| mean ± SD | 11 ± 21 | ||
| (range) | (1–68) | ||
| Asphericity (ASP) in % | |||
| mean ± SD | 45.0 ± 20.4 | ||
| (range) | (24.5–84.3) | ||
| Duration of disease in months | |||
| mean ± SD | 24 ± 37 | ||
| (range) | (1–128) | ||
| Presence of metastasis | 7/13 (54%) | ||
| Drug therapy | 6/13 (46%) |
* partial expression of glucagon. PNET-T = tumorous region in participants with pancreatic neuroendocrine tumor; PNET-NT = nontumorous region in participants with pancreatic neuroendocrine tumor; CTR = control; CI = confidence interval; NEC = neuroendocrine carcinoma; NET = neuroendocrine tumor; SD = standard deviation; SWS = shear wave speed; SUVmax = maximum standardized uptake value; PET/CT = positron emission tomography-computed tomography; PET/MRI = positron emission tomography-magnetic resonance imaging.